ICNMD 2024

  • #ICNMD2024
SUBSCRIBE TO MAILING LIST
Facebook-f Twitter Linkedin

Call for Abstracts

ICNMD 2024 Late Breaking Abstracts Has Closed.

The Scientific Program Committee of the 18th International Congress on Neuromuscular Diseases invites the submission of late breaking scientific abstracts. Please read the details below carefully before submitting an abstract.

Submit Your Abstract

Important Dates

Abstract Submission Closed
Abstract Notifications29 May 2024
Presenting Author Registration Deadline19 June 2024
Late Breaking Abstracts Closed
Late Breaking Abstracts Deadline30 June 2024
Late Breaking Abstract Notifications22 July 2024
Late Breaking Abstract Presenter Registration Deadline5 August 2024
Congress Dates25 – 29 October 2024

Abstract Submission Guidelines

Authors are asked to present their work with precise and clear objectives, directly related to their evidence and scientific support to support their research or clinical study. An international panel of reviewers will review all abstracts anonymously.
  • Abstract word limit: 500 words
  • Title word limit: 15 words
  • Number of images and tables: 1
  • Number of co-authors per abstract: no limit
  • Number of presenting authors per abstract: 1
  • Number of abstracts a presenting author can present: no limit
  • Abstracts will be accepted in English only
  • Case reports presented as abstract for poster display are accepted.
  • Encore abstracts:  an abstract that has previously been presented at another meeting will be considered.
  • Abstracts can only be submitted online, via the submission portal. Paper, email submission and USB/CD submission will NOT be accepted.
  • ICNMD2024 organizers expect that all abstracts selected for presentation will be presented by the presenting author and that submitted abstracts will not be withdrawn.
  • Please do not submit an abstract if you are not able to travel to the Congress (Perth, Australia) and present it in the form selected.
  • Posters by representatives of commercial companies are accepted with the authors’ names (and any professional designation such as MD, or Researcher etc.) only, and are not to include names or associations with the commercial companies that they represent. Generic product names may be used but not company product names.
  • NEW: content generated by AI is acceptable. However, It is mandatory to disclose this at the end of the abstract body.

Topic Group 1 - Muscle Diseases. Genetic and Acquired Myopathies: Clinical Features, Pathophysiology, Therapy

  • Dystrophinopathies
  • Muscle Dystrophies (Non-Dystrophinopathies)
  • Limb Girdle Muscular Dystrophies
  • Facioscapulohumeral Muscular Dystrophies
  • Oculopharyngeal Muscular Dystrophy
  • Congenital Myopathies and congenital muscular dystrophies
  • Myotonic Dystrophies
  • Muscle Channelopathies and Related Disorders
  • Metabolic Myopathies: Glycogen, Lipids and Mitochondrial Myopathies
  • Distal Myopathies
  • Myofibrillar Myopathies
  • Inflammatory / Immune-mediated Myopathies including Inclusion Body Myositis (IBM)
  • Hereditary Inclusion Body Myopathies (hIBM)
  • Toxic / Endocrine / Other Acquired Myopathies
  • Other Myopathies
  • Advances in the treatment of muscle diseases.

Topic Group 2 - Diseases of Neuromuscular Junction: Clinical Features, Pathophysiology, Therapy

  • Myasthenia Gravis
  • Myasthenic Syndromes
  • Congenital Myasthenic syndrome
  • Advances in the treatment of Neuromuscular Junction diseases.

Topic Group 3 - Peripheral Neuropathies, including Cranial Nerves: Clinical Features, Pathophysiology, Therapy

  • Hereditary Peripheral Neuropathies
  • Immune-mediated Neuropathies
  • Neuropathies Associated with Monoclonal Gammopathy / Paraneoplastic
  • Metabolic, Toxic and Iatrogenic Neuropathies
  • Infectious Peripheral Neuropathies (including Leprosy, HIV)
  • Advances in treatment of Peripheral Neuropathies
  • Small fibers and painful neuropathies
  • Autonomic neuropathies
  • Others

Topic Group 4 - Motor Neuron Diseases:

  • ALS: Epidemiology and Clinical Features,
  • ALS: Biology, Pathophysiology, Genetics
  • ALS: Therapy
  • Primary Progressive Lateral Sclerosis Variant
  • non 5q SMA/distal SMA/ Hereditary Motor Neuropathies
  • Post poliomyelitis Syndrome
  • Bulbospinal muscular atrophy
  • Biomarkers in MND
  • Spinal Muscular Atrophies: Epidemiology and Clinical Features,
  • Spinal Muscular Atrophies: Pathophysiology, Genetics
  • Spinal Muscular Atrophies: Treatment
  • Advances in treatment of Motor Neuron Diseases

Topic Group 5 –Diagnostic Methods and assessment in Neuromuscular Diseases

  • Ultrasound
  • MRI
  • Electrophysiology
  • Neuromuscular Pathology: Muscle and Nerve Biopsy
  • Genetics in Neuromuscular Diseases including Biochemical/Molecular Techniques and next generation sequencing.
  • Small Nerve Fibre Evaluation by Skin Biopsy
  • Other Biomarkers
  • Swallowing evaluation in neuromuscular diseases
  • Cardiac and respiratory issues in neuromuscular diseases.
  • Orthopedic issues in neuromuscular diseases.
  • Outcome measures and clinimetry

Topic Group 6 - Basic Sciences in Neuromuscular Diseases

  • Muscle Homeostasis / Muscle Regeneration
  • Muscle Structure / Muscle Development / Muscle Growth
  • Muscle Atrophy / Degeneration
  • Nuclear Envelope / Nuclear Matrix of Muscle Cell
  • Ion Channel Function in Neuron and Muscle
  • Nerve development/nerve degeneration and regeneration
  • Mechanisms of myelination and demyelination
  • Immune Mechanisms in Neuromuscular Diseases
  • Fundamental Approaches to Motor Neuron, Axon and Related Structures
  • Neuromuscular Junction
  • Axonal transport / axonal degeneration
  • Myelin and Schwann cell

Topic Group 7 – COVID-19 related issues in Neuromuscular Diseases

Topic Group 8 - Patient Related Issues

  • Palliative Care

Topic Group 9 – History

Topic Group 10 - Hereditary Ataxias/Spastic Paraplegias

  • All authors must complete a conflict of interest on their abstract submission.
  • If your research has been granted any commercial or institutional support, you will be asked to disclose this during the submission process.
  • An international panel of reviewers will review all abstracts anonymously.
  • Submitting an abstract does not automatically register you for ICNMD2024; You must register to the Congress once you receive the notification letter.
  • Please note, abstracts with the top scores will be invited to present their work (as oral presentations) in one of the sessions at ICNMD 2024.

Frequently Asked Questions

With whom does the abstract Copyright stay?

  • The copyright remains with the authors, but ICNMD Congress retains the rights to share or republish.

Does ICNMD 2024 Accepts Case reports?

  • Yes, case reports presented as abstract for poster display are accepted.

Does ICNMD 2024 Accepts Encore abstracts?

  • Yes, an abstract that has previously been presented at another meeting will be considered.

Does ICNMD 2024 Accepts Posters by representatives of commercial companies?

  • Posters by representatives of commercial companies are accepted with the authors’ names (and any professional designation such as MD, or Researcher etc.) only, and are not to include names or associations with the commercial companies that they represent. Generic product names may be used but not company product names.

Contact

For any inquiries, please contact icnmd-program@icsevents.com. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.